Clovis Oncology Announces European Commission Authorization of Rubraca

BOULDER, Colo.--( BUSINESS WIRE)--Clovis Oncology, Inc. (NASDAQ: CLVS) today announced that the European Commission (EC) has authorized Rubraca (rucaparib) as monotherapy treatment of adult patients with platinum-sensitive, relapsed or progressive, BRCA mutated (germline and/or somatic), high-grade epithelial ovarian, fallopian tube, or primary peritoneal cancer, who have been treated with two or more prior lines of platinum based chemotherapy, and who are unable to tolerate further platinum based chemotherapy.

Certain confirmatory post-marketing commitments are required as part of this conditional authorization.